Mondaq Canada: Food, Drugs, Healthcare, Life Sciences > Life Sciences, Biotechnology & Nanotechnology
Torys LLP
Final amendments to the Patented Medicines Regulations have been announced by the Government of Canada giving the Patented Medicine Prices Review Board
Miller Thomson LLP
Drugs and medical devices are integral parts of the Canadian health care system, used by many to treat and prevent a variety of conditions.
Smart & Biggar
On June 10, 2019, the Regulations Amending the Food and Drug Regulations (Serious Adverse Drug Reaction Reporting – Hospitals)and Regulations Amending the Medical Devices Regulations
Smart & Biggar
The Canadian Agency for Drugs and Technologies in Health (CADTH) released Issue 8 of its Pharmaceutical Reviews Update announcing updates
Smart & Biggar
On June 27, 2019, Health Canada published Drug and medical device highlights 2018: Helping you maintain and improve your health, an annual highlights report for 2018.
Norton Rose Fulbright Canada LLP
The Competition Bureau recently conducted a preliminary investigation into possible competition concerns arising from a proposal to include a clause in a procurement contract that would restrict off-label use of a vaccine.
Fasken (French)
Le présent bulletin est destiné aux fabricants de produits pharmaceutiques et d'instruments médicaux et à ceux qui en font la promotion.
Torys LLP
On June 28, the Federal Court of Appeal (FCA) affirmed the lower court's approach to patent review in determining whether the Patented Medicine Prices Review Board (PMPRB)
Norton Rose Fulbright Canada LLP
Dans TearLab Corporation c. I-MED Pharma Inc, 2019 FCA 179, la Cour d'Appel Fédérale (CAF) a confirmé le rejet de l'action en contrefaçon de brevet de TearLab contre I-MED.
Smart & Biggar
As of June 30, Health Canada had approved 16 biosimilars, based on 11 comparator products (3 in 2019).
Smart & Biggar
Food and Drugs Act amendments: Bill C-97, tabled in April, proposed amendments to the Food and Drugs Act, including a new framework for "Advanced Therapeutic Products"
Fasken
The consultation is open for 60 days ending on September 3, 2019.
Fasken
On June 26, 2019, the federal government, under the authorities granted by the Protecting Canadians from Unsafe Drugs Act (Vanessa's Law), adopted new mandatory reporting requirements for hospitals across the country.
Norton Rose Fulbright Canada LLP
The Federal Court of Appeal has provided new guidance on the proper approach to the "patent pertaining" analysis used by the Patented Medicine Prices Review Board, including on the identification of the medicine ...
Borden Ladner Gervais LLP
Traditionally, Health Canada has only required drug and medical device manufacturers to report serious adverse drug reactions and adverse events involving these products
Smart & Biggar
On June 15, 2019, the Regulations Amending Certain Regulations Made Under the Food and Drugs Act (Post-market Surveillance of Medical Devices) (Regulations) were pre-published
Stikeman Elliott LLP
In 2014, amendments to the Food and Drugs Act gave the federal Minister of Health authority with respect to the safety of drugs, medical devices and other therapeutic devices that are already
Torys LLP
The Federal Court has dismissed an application for judicial review by Alexion Pharmaceuticals Inc. (Alexion) in relation to a decision of the Patented Medicine Prices
Borden Ladner Gervais LLP
On March 13, 2019, the Canadian Competition Bureau issued revised Intellectual Property Enforcement Guidelines (the IPEGs).
Stikeman Elliott LLP
En 2014, des modifications apportées à la Loi sur les aliments et drogues ont conféré au ministre fédéral de la Santé le pouvoir de régir la sûreté des médicaments, des instruments médicaux et des autres appareils thérapeutiques qui sont déjà sur le marché.
Latest Video
Most Popular Recent Articles
Torys LLP
Final amendments to the Patented Medicines Regulations have been announced by the Government of Canada giving the Patented Medicine Prices Review Board
Norton Rose Fulbright Canada LLP
The Federal Court of Appeal has provided new guidance on the proper approach to the "patent pertaining" analysis used by the Patented Medicine Prices Review Board, including on the identification of the medicine ...
Torys LLP
On June 28, the Federal Court of Appeal (FCA) affirmed the lower court's approach to patent review in determining whether the Patented Medicine Prices Review Board (PMPRB)
Torys LLP
A raft of changes to the Canadian medical device regulatory landscape were seen in 2018, several of which were directed at harmonizing Canada's approach to medical device regulation with those of other countries
Borden Ladner Gervais LLP
Traditionally, Health Canada has only required drug and medical device manufacturers to report serious adverse drug reactions and adverse events involving these products
Smart & Biggar
In 2018 we reported on a number of developments in life sciences IP and regulatory law. Our most-read articles were: #1 a June update on biosimilars (authored by Urszula Wojtyra);
Norton Rose Fulbright Canada LLP
The Competition Bureau recently conducted a preliminary investigation into possible competition concerns arising from a proposal to include a clause in a procurement contract that would restrict off-label use of a vaccine.
Miller Thomson LLP
Drugs and medical devices are integral parts of the Canadian health care system, used by many to treat and prevent a variety of conditions.
Gowling WLG
In late 2018, a series of news articles took aim at Canada's regulation of medical devices, alleging that Health Canada's medical device approval and adverse event monitoring systems were severely
Fasken
The consultation is open for 60 days ending on September 3, 2019.
Article Search Using Filters
Related Topics
Mondaq Advice Centre (MACs)
Popular Authors
Popular Contributors
Up-coming Events Search
Tools
Font Size:
Translation
Channels
Mondaq on Twitter
Partners
In association with